FOXP3 and in situ carcinoma: The authors focused on FOXP3+ cells, a marker for regulatory T cells (Tregs), in close proximity to CIS cancer cells and proposed that Tregs enrichment adjacent to CIS could serve as a biomarker at the time of CIS diagnosis, prior to BCG instillation.